Disc Medicine Stock Jumps After Phase 3 Trial Success And FDA Refiling Plan

What happened: Disc Medicine said its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X linked protoporphyria met all primary and secondary endpoints, and it plans to resubmit an FDA filing by late 2026 alongside a US$350 million follow on equity Why it matters: The data and refiling plan give a clearer regulatory path for a zero revenue platform where bitopertin is the lead asset, while the raise points to a capital intensive launch build. Attention turns to how the investment narrative absorbs the Phase 3 wins, particularly the gain in pain free light exposure. Market: +38.9% today ($78.93), -0.2% YTD, 17.2x vol — as of 23:45 UTC

Disc Medicine said its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria and X linked protoporphyria met all primary and secondary endpoints, and it plans to resubmit an FDA filing by late 2026 alongside a US$350 million follow on equity

The data and refiling plan give a clearer regulatory path for a zero revenue platform where bitopertin is the lead asset, while the raise points to a capital intensive launch build. Attention turns to how the investment narrative absorbs the Phase 3 wins, particularly the gain in pain free light exposure. Market: +38.9% today ($78.93), -0.2% YTD, 17.2x vol — as of 23:45 UTC